Calithera Biosciences (NASDAQ:CALA) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Calithera Biosciences (NASDAQ:CALA) in a report released on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.

Calithera Biosciences Price Performance

CALA opened at $0.05 on Tuesday. Calithera Biosciences has a 12 month low of $0.01 and a 12 month high of $3.68. The stock has a market cap of $243,600.00, a P/E ratio of 0.00 and a beta of 0.28. The stock’s 50 day moving average price is $0.05 and its 200 day moving average price is $0.11.

Hedge Funds Weigh In On Calithera Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CALA. Goldman Sachs Group Inc. boosted its stake in Calithera Biosciences by 143.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 123,739 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 72,865 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Calithera Biosciences by 13.8% during the 3rd quarter. Renaissance Technologies LLC now owns 114,555 shares of the biotechnology company’s stock valued at $337,000 after purchasing an additional 13,855 shares in the last quarter. Alyeska Investment Group L.P. bought a new position in Calithera Biosciences during the 1st quarter valued at $404,000. Affinity Asset Advisors LLC bought a new position in Calithera Biosciences during the 1st quarter valued at $404,000. Finally, Vanguard Group Inc. boosted its stake in shares of Calithera Biosciences by 23.4% during the 3rd quarter. Vanguard Group Inc. now owns 141,217 shares of the biotechnology company’s stock worth $415,000 after acquiring an additional 26,800 shares in the last quarter. 0.02% of the stock is owned by institutional investors.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc was incorporated in 2010 and is headquartered in South San Francisco, California.